Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest

By Kim Won  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1311-1318

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

By Chi Kim   Chia Stephen   Dixon Ross   Newman Michael   Wacher Vince   Sikic Branimir   Gelmon Karen  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 311-315

Springer Publishing Company

Access to resources Recommend Favorite

P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor

By  

Drug Metabolism Letters, Vol. 4, Iss. 4, 2010-12 ,pp. : 202-212

Bentham Science Publishers

Access to resources Recommend Favorite

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

By Beumer Jan-Hendrik   Buckle Tessa   Ouwehand Mariet   Franke Niels   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos   Tellingen Olaf  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat

By Silva Renata   Sousa Emília   Carmo Helena   Palmeira Andreia   Barbosa Daniel   Gameiro Mariline   Pinto Madalena   Lourdes Bastos Maria   Remião Fernando  

Archives of Toxicology, Vol. 88, Iss. 4, 2014-04 ,pp. : 937-951

Springer Publishing Company

Access to resources Recommend Favorite